Tracers / [18F]AV-45
[18F]AV-45
Also written as [18F]AV-45; [18F]florbetapir; [F-18]AV-45; [F-18]florbetapir; AV-45; F-18 AV-45; F-18 Florbetapir
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- Approved
- Syntheses indexed
- 8
What it is
- Compound class
- Radiolabelled stilbene derivative (amyloid-binding small molecule)
- Target / mechanism
- β-amyloid neuritic plaques (Kd approx. 3.7 nM in postmortem brain homogenates) PMID 23527322
- Clinical application
- PET imaging of the brain to estimate β-amyloid neuritic plaque density in adults with cognitive impairment, for evaluation of Alzheimer's disease and other causes of cognitive decline FDA label NDA202008
- Theranostic pair
- —
Regulatory status
- FDA
- 2012, Amyvid, Avid Radiopharmaceuticals (Eli Lilly) FDA (Drugs@FDA/openFDA): NDA202008, approved 2012-04-06
- EMA (centralised)
- 2013, Amyvid, Eli Lilly EMA medicines register export (2026-09-09): EMEA/H/C/002422, 'Authorised', authorised 14 Jan 2013
- Other approvals
- —
- Brand names
- Amyvid
Clinical use
- Typical injected activity
- 370 MBq (10 mCi) as a single IV bolus FDA label NDA202008 (human clinical dosing)
- Uptake time
- 10-minute PET scan performed within 90 minutes after administration FDA label NDA202008
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| TRACERlab FX FN GE HealthCare | fixed tubing | HPLC | 14.8 ± 2.1% no | >95% | AV-45 precursor (O-tosylated precursor) Wuxi Jiangyuan Industrial Technology and Trade Corporation | 35494660 2022 Front Chem Radiochemical synthesis and purification of [18F] AV-45 was carried out using a Tracerlab FXF-N Synthesizer — the average non-decay corrected radiochemical yield of [18F]AV-45 was 14.8 ± 2.1% (n = 4) |
| BNU F-A2 | custom manifold | SPE | 33.6 ± 5.2% (no decay corrected); 50.1 ± 7.9% (decay corrected) yes | > 95% | 1 (-OTs derivative) | 21055622 2010 Nucl Med Biol a radiosynthesis module (BNU F-A2) — the automated synthesis yield was 33.6 ± 5.2% (no decay corrected, n = 4), 50.1 ± 7.9% (decay corrected) in 50 min at a quantity level of 10~100 mCi (370~3700 MBq) |
| — | — | SPE | 42.7 ± 5.9% yes | greater than 95% | O-tosylated precursor | 31697847 2020 J Labelled Comp Radiopharm |
| — | — | SPE | 14.2% | >95% | — | 37526186 2024 Curr Med Chem produced in a simple, stable, and repeatable manner on the Tracerlab FXF-N platform — the radiochemical yield was 14.2 % ± 2.7% (n = 6) |
| — | — | — | 31.0%±2.8% no | >98 | AV-105 | 38149774 2023 Hell J Nucl Med can be easily and quickly prepared by the All in One radiochemical synthesis module — the uncorrected synthesis efficiency was about 31.0%±2.8% |
| — | — | — | — | — | — | 31554771 2019 Kaku Igaku radiopharmaceutical synthesizer NEPTIS plug - 01 |
| — | — | — | 25.4±7.7% | 95.3±2.2% | tosylate precursor | 20638295 2010 Appl Radiat Isot using a tosylate precursor with Sumitomo modules for radiosynthesis under GMP-compliant conditions — The overall yield was 25.4+/-7.7% |
| — | — | — | — | — | — | 42142951 2026 J Nucl Cardiol |
Need this precursor?We can point you to suppliers for [18F]AV-45, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]AV-45.
Get in touchNotes
Added from reverse module search (stage 6); 9 article(s) with F-18.